Openly accessible

Brain metastases in lung cancers with emerging targetable fusion drivers

Tan, Aaron C, Itchins, Malinda and Khasraw, Mustafa 2020, Brain metastases in lung cancers with emerging targetable fusion drivers, International journal of molecular sciences, vol. 21, no. 4, pp. 1-12, doi: 10.3390/ijms21041416.

Attached Files
Name Description MIMEType Size Downloads

Title Brain metastases in lung cancers with emerging targetable fusion drivers
Author(s) Tan, Aaron C
Itchins, Malinda
Khasraw, MustafaORCID iD for Khasraw, Mustafa orcid.org/0000-0003-3249-9849
Journal name International journal of molecular sciences
Volume number 21
Issue number 4
Article ID 1416
Start page 1
End page 12
Total pages 12
Publisher MDPI
Place of publication Basel, Switzerland
Publication date 2020-02-02
ISSN 1661-6596
1422-0067
Keyword(s) Science & Technology
Life Sciences & Biomedicine
Physical Sciences
Biochemistry & Molecular Biology
Chemistry, Multidisciplinary
Chemistry
brain metastases
fusion drivers
non-small cell lung cancer
targeted therapy
Summary The management of non-small cell lung cancer (NSCLC) has transformed with the discovery of therapeutically tractable oncogenic drivers. In addition to activating driver mutations, gene fusions or rearrangements form a unique sub-class, with anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) targeted agents approved as the standard of care in the first-line setting for advanced disease. There are a number of emerging fusion drivers, however, including neurotrophin kinase (NTRK), rearrangement during transfection (RET), and neuregulin 1 (NRG1) for which there are evolving high-impact systemic treatment options. Brain metastases are highly prevalent in NSCLC patients, with molecularly selected populations such as epidermal growth factor receptor (EGFR) mutant and ALK-rearranged tumors particularly brain tropic. Accordingly, there exists a substantial body of research pertaining to the understanding of brain metastases in such populations. Little is known, however, on the molecular mechanisms of brain metastases in those with other targetable fusion drivers in NSCLC. This review encompasses key areas including the biological underpinnings of brain metastases in fusion-driven lung cancers, the intracranial efficacy of novel systemic therapies, and future directions required to optimize the control and prevention of brain metastases.
Language eng
DOI 10.3390/ijms21041416
Indigenous content off
Field of Research 0399 Other Chemical Sciences
0604 Genetics
0699 Other Biological Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30136891

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in TR Web of Science
Scopus Citation Count Cited 5 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 12 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 11 May 2020, 14:09:09 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.